Helius Medical Technologies Inc Class A HSDT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HSDT is a good fit for your portfolio.
News
-
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
-
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
-
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
-
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
-
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
-
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
-
Thinking about buying stock in SoundHound AI, Macy's, Ainos, Helius Medical Technologies, or Renalytix?
-
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
Trading Information
- Previous Close Price
- $4.44
- Day Range
- $4.42–4.69
- 52-Week Range
- $4.29–14.44
- Bid/Ask
- $4.44 / $4.98
- Market Cap
- $3.99 Mil
- Volume/Avg
- 5,124 / 433,163
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.25
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 22
- Website
- https://www.heliusmedical.com
Profitability
|
Metric
|
HSDT
|
|---|---|
Return on Assets (Normalized) | −88.39% |
Return on Equity (Normalized) | −213.44% |
Return on Invested Capital (Normalized) | −215.04% |
Return on Assets
HSDT
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Jfhszmnz | Ltstxpc | $185.4 Bil | |
SYK
| Stryker Corp | Pbqfvnthb | Mlj | $127.7 Bil | |
BSX
| Boston Scientific Corp | Zvvmfdt | Bkgkqn | $107.6 Bil | |
MDT
| Medtronic PLC | Frqcflry | Pxnwp | $105.9 Bil | |
DXCM
| DexCom Inc | Tlqjtmpjqh | Fvmzd | $54.7 Bil | |
EW
| Edwards Lifesciences Corp | Yygtphgb | Jdfjvm | $52.0 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Gnmfrxwj | Lkpj | $24.6 Bil | |
ALGN
| Align Technology Inc | Kntmmcwf | Zhmqp | $23.4 Bil | |
PHG
| Koninklijke Philips NV ADR | Fhqhvqmv | Pnqgww | $18.7 Bil | |
PODD
| Insulet Corp | Mdyngfsjw | Rlmchnj | $11.6 Bil |